Resonant Capital Advisors LLC Acquires 410 Shares of Eli Lilly and Company $LLY

Resonant Capital Advisors LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 6,123 shares of the company’s stock after acquiring an additional 410 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $5,632,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of LLY. Spire Wealth Management lifted its holdings in shares of Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after buying an additional 592 shares during the period. Coldstream Capital Management Inc. increased its position in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares during the period. Iams Wealth Management LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth about $754,000. Finally, Militia Capital Partners LP grew its stake in shares of Eli Lilly and Company by 333.3% during the 3rd quarter. Militia Capital Partners LP now owns 2,600 shares of the company’s stock valued at $1,984,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.8%

Shares of LLY stock opened at $1,233.32 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The company’s fifty day moving average price is $1,078.08 and its 200-day moving average price is $1,030.27. The company has a market capitalization of $1.16 trillion, a price-to-earnings ratio of 43.81, a PEG ratio of 1.49 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the business earned $3.34 earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and reiterated an overweight rating, signaling continued upside expectations for the stock. Benzinga report on JPMorgan price target raise
• Positive Sentiment: Shares hit a fresh 52-week high, reflecting momentum buying and strong investor enthusiasm around Lilly’s GLP-1 and obesity-treatment pipeline. CNBC report on Eli Lilly hitting 52-week high
• Positive Sentiment: Weak results from Kailera Therapeutics’ weight-loss pill IPO appear to have indirectly helped Lilly by reinforcing the market’s confidence in Lilly’s lead position in obesity drugs. Yahoo Finance article on Kailera setback and Lilly market cap
• Positive Sentiment: Commentary from Jim Cramer and other market-watch pieces remained constructive on biotech and Lilly’s growth story, suggesting investors still see the company as a core winner in the GLP-1 boom. 247WallSt Cramer commentary on Eli Lilly
• Neutral Sentiment: Several articles highlighted Lilly as a top healthcare stock to own and as a long-term growth story, but these were mainly opinion pieces rather than new company-specific developments. Motley Fool article on Eli Lilly stock
• Neutral Sentiment: Recent partnership and China-related business updates show Lilly is still actively managing its broader pipeline and regional strategy, but they appear less important than the obesity franchise news for today’s move. Yahoo Finance article on R&D collaboration and China rights transfer
• Negative Sentiment: Some coverage continues to point to regulatory and pricing-policy risks for Lilly, which could weigh on sentiment over time even as the stock remains strong now. Yahoo Finance article on regulatory and pricing policy challenges

Analyst Ratings Changes

Several equities analysts have recently weighed in on LLY shares. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Barclays boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Bank of America increased their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,243.22.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.